In an age of crisis, can the biopharma industry withstand global shocks?
2020 revealed uncomfortable truths about a sector that has become a globalized system of production, trade, and distribution. At no point in the modern era have the health and resilience of the biopharma industry been more crucial.
To assess the strength of the global industry, Cytiva created the Global Biopharma Resilience Index, which scores and ranks 20 countries on five factors: supply chain resilience, access to talent, strength of the R&D ecosystem, quality and agility of manufacturing processes, and effectiveness of government policy in supporting the industry. The overall index score for each country acts as a proxy for the strength of its biopharma industry.
Cytiva and The Financial Times will provide important insights from the new Resilience Index and the state of biopharma amid its biggest challenge yet.